A Case of Psoriasis Exacerbated by Radioactive Iodine Therapy

Vol. 26, No. 6, 2014 785 Received September 5, 2013, Revised January 18, 2014, Accepted for publication February 1, 2014 Corresponding author: Tae Yoon Kim, Department of Dermatology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 137-701, Korea. Tel: 82-2-2258-1380, Fax: 82-2-599-9950, E-mail: [email protected] This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http:// creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. improvement was observed in the area without any complication. We gradually expanded the treatment area. During the sessions, mild blisters developed after treatment with 2.7 J/cm or higher; however, they disappeared without leaving hyperor hypopigmentation. A total of seven sessions of laser treatment, with energy between 2.0 and 2.7 J/cm, were successfully made from March 2002 to November 2007 (Fig. 2), and the interval between treatments was several months to 2 years. Thereafter, she was lost to follow-up for 4 years because of personal reasons. In March 2012, she visited our clinic for treatment of the remaining lesions. There was neither a recurrence of RAPK nor treatment-related adverse effects on the previously treated area. We treated the residual lesions with same parameters as previously used, and the clinical effect was also good. Recently, Fahad et al. introduced the use of 755-nm Q-switched alexandrite laser as an effective modality to treat RAPK. In our case, the successful depigmentation with 532-nm QSND was made without a significant adverse reaction. We also observed the maintenance of clinical improvement for 10 years without any repigmentation on the treated area. Thus, 532-nm QSND may play a central role in the treatment of RAPK. As this is a single case of clinical experience, a follow-up study will be needed.